(4-cyclohexylpiperazin-1-yl)(6-(pyridin-4-yl)-6-azaspiro[2.5]-octan-1-yl)methanone | 1088498-00-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (4-cyclohexylpiperazin-1-yl)(6-(pyridin-4-yl)-6-azaspiro[2.5]-octan-1-yl)methanone
• 英文别名: (4-cyclohexyl-piperazin-1-yl)-(6-pyridin-4-yl-6-aza-spiro[2.5]oct-1-yl)-methanone；(4-cyclohexylpiperazin-1-yl)-(6-pyridin-4-yl-6-azaspiro[2.5]octan-2-yl)methanone
• CAS: 1088498-00-3
• 化学式: C₂₃H₃₄N₄O
• 分子量: 382.549
• InChiKey: VBIOHMFBWGEKCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  39.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-Cbz-6-氮杂螺[2.5]辛烷-1-羧酸 在 5%-palladium/activated carbon 氢气 、 potassium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 生成 (4-cyclohexylpiperazin-1-yl)(6-(pyridin-4-yl)-6-azaspiro[2.5]-octan-1-yl)methanone
  参考文献：
  名称：

  WO2008/147314

  摘要：

  公开号：

文献信息

• Spirocyclopropyl Piperidine Derivatives
  申请人：Bernstein Peter

  公开号：US20100168105A1

  公开（公告）日：2010-07-01

  Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

  本文公开了至少一种哌啶衍生物，至少一种药物组合物，其中包括本文所公开的至少一种哌啶衍生物，用于治疗至少一种与组织胺H3受体相关的疾病。
• WO2008/147314
  申请人：——

  公开号：——

  公开（公告）日：——
• SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP2162452A1

  公开（公告）日：2010-03-17
• [EN] SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SPIROCYCLOPROPYL
  申请人：ASTRAZENECA AB

  公开号：WO2008147314A1

  公开（公告）日：2008-12-04

  [EN] Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith
  [FR] L'invention concerne au moins un dérivé de pipéridine, au moins une composition pharmaceutique comportant au moins un dérivé de pipéridine décrit ici pour traiter avec celui-ci au moins un état associé au récepteur H3 d'histamine.
• Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition
  作者：Dean G. Brown、Peter R. Bernstein、Andrew Griffin、Steve Wesolowski、Denis Labrecque、Maxime C. Tremblay、Mark Sylvester、Russell Mauger、Phillip D. Edwards、Scott R. Throner、James J. Folmer、Joseph Cacciola、Clay Scott、Lois A. Lazor、Mehrnaz Pourashraf、Vijayaratnam Santhakumar、William M. Potts、Simon Sydserff、Pascall Giguère、Carine Lévesque、Mohammed Dasser、Thierry Groblewski

  DOI：10.1021/jm4014828

  日期：2014.2.13

  A new series of potent and selective histamine-3 receptor (H3R) antagonists was identified on the basis of an azaspiro[2.5]octane carboxamide scaffold. Many scaffold modifications were largely tolerated, resulting in nanomolar-potent compounds in the H3R functional assay. Exemplar compound 6s demonstrated a selective profile against a panel of 144 secondary pharmacological receptors, with activity at only sigma 2 (62% at 10 mu M). Compound 6s demonstrated free-plasma exposures above the IC50 (similar to 50x) with a brain-to-plasma ratio of similar to 3 following intravenous dosing in mice. At three doses tested in the mouse novel object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant response compared with the control group. This series represents a new scaffold of H-3 receptor antagonists that demonstrates in vivo exposure and efficacy in an animal model of cognition.